Quantum Biopharma Ltd

Quantum Biopharma operates with a current liquidity position of $1.91 million in cash and equivalents, while its total liabilities amount to $4.24 million. The company's liquidity FPT (free cash flow to total liabilities) is negative, indicating a liquidity risk. The current ratio of 1.07 suggests the company is barely able to cover its short-term obligations with its current assets. The debt-to-equity ratio of 0.27 indicates a relatively low leverage position, with total equity of $6.92 million and long-term debt of $1.88 million. The company's profitability is currently negative, with a net loss of $26.18 million and an operating loss of $16.75 million. Return on equity (ROE) is -3.78, and return on assets (ROA) is -2.34, both significantly below the industry median for biotechnology firms. These metrics suggest the company is not generating returns for shareholders or efficiently utilizing its assets. Quantum Biopharma's revenue is not segmented by product or geography in the available data, but the company's exposure is likely concentrated in the biotechnology and medical research sectors. Given the nature of the industry, the company's performance is highly dependent on the success of its R&D pipeline and regulatory approvals. The company's growth trajectory is currently negative, with a free cash flow of -$26.41 million and an operating cash flow of -$8.24 million. Analysts have set a uniform price target of $45.00, but the company's current financial position does not support a positive outlook for the near term. The lack of positive cash flow and the high net loss suggest the company is in a growth phase that is not yet profitable. The risk assessment indicates a low probability of dilution and low liquidity risk, but the company's negative cash flows and high net loss present a significant operational risk. The absence of immediate filing-based liquidity or dilution flags is a positive sign, but the company's financial performance suggests a need for close monitoring of its capital structure and cash flow management. Recent events and filings do not indicate any major changes in the company's strategic direction or financial position. The company continues to operate with a focus on R&D and product development, but the lack of positive financial performance suggests that the company is still in the early stages of its growth cycle.